PDF herunterladen
Pharmacopsychiatry 2017; 50(02): 56-63
DOI: 10.1055/s-0042-112818
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms

Diego Novick
1   Eli Lilly and Company, Windlesham, Surrey, UK
,
William Montgomery
2   Eli Lilly Australia Pty Ltd, West Ryde, Australia
,
Tamas Treuer
3   Neuroscience Research, Eli Lilly and Company, Budapest, Hungary
,
Maria Victoria Moneta
4   Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
,
Josep Maria Haro
4   Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 11. Juni 2015
revised 25. Mai 2016

accepted 11. Juli 2016

Publikationsdatum:
16. Februar 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Introduction

This study assessed the comparative effectiveness of antipsychotics in the treatment of patients with schizophrenia presenting with prominent negative symptoms and no-to-mild positive symptoms.

Methods

Data were taken from a 3-year prospective, international, observational study (n=17 384). This post-hoc study focused on 3 712 patients who started antipsychotic monotherapy and had moderate-to-severe negative symptoms and no-to-mild positive symptoms (Clinical Global Impression-Severity Scale [GGI-SCH]). Patients were classified into 3 treatment cohorts: olanzapine, other atypicals and typicals. Multiple regression analyses were performed.

Results

All treatment groups experienced improvement in negative symptoms and social functioning during follow-up. The adjusted mean change in the CGI-SCH negative symptoms scores during follow-up was greater for olanzapine-treated patients by 0.220 (p<0.001) (vs. other atypicals) and by 0.453 (p<0.001) (vs. typicals). Olanzapine-treated patients were also most likely to achieve response of negative symptoms and improvement in social functioning, and to stay on the initial medication longer.

Discussion

Patients with schizophrenia treated with antipsychotics experienced improvement in negative symptoms and social functioning during follow-up. Olanzapine appeared to be more effective compared with other antipsychotics.

Key words

antipsychotics - negative symptoms - schizophrenia - SOHO
 

  • References

  • 1 Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063-2072
    CrossrefPubMedGoogle Scholar
  • 2 Velligan DI, Mahurin RK, Diamond PL. et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 1997; 25: 21-31
    CrossrefPubMedGoogle Scholar
  • 3 Lysaker PH, Davis LW. Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. Health Quality Life Outcomes 2004; 2: 15
    CrossrefPubMedGoogle Scholar
  • 4 Lysaker PH, Lancaster RS, Nees MA. et al. Attributional style and symptoms as predictors of social function in schizophrenia. J Rehabil Res Dev 2004; 41: 225-232
    CrossrefPubMedGoogle Scholar
  • 5 Norman RM, Malla AK, McLean T. et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000; 102: 303-309
    CrossrefPubMedGoogle Scholar
  • 6 Milev P, Ho BC, Arndt S. et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506
    CrossrefPubMedGoogle Scholar
  • 7 Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull 2006; 32: 246-249
    CrossrefPubMedGoogle Scholar
  • 8 Ho BC, Nopoulos P, Flaum M. et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998; 155: 1196-1201
    CrossrefPubMedGoogle Scholar
  • 9 Rocca P, Montemagni C, Castagna F. et al. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 373-379
    CrossrefPubMedGoogle Scholar
  • 10 Rabinowitz J, Levine SZ. Garibaldi G et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012; 137: 147-150
    CrossrefPubMedGoogle Scholar
  • 11 Carpenter Jr WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583
    CrossrefPubMedGoogle Scholar
  • 12 Moller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993; 3: 1-11
    CrossrefPubMedGoogle Scholar
  • 13 Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215-228
    CrossrefPubMedGoogle Scholar
  • 14 King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998; 8: 33-42
    CrossrefPubMedGoogle Scholar
  • 15 Moller HJ. Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl. 04) 99-107
    CrossrefPubMedGoogle Scholar
  • 16 Darba J, Minoves A, Rojo E. et al. Efficacy of second-generation antipsychotics in the treatment of negative symptoms of schizophrenia: a meta-analysis of randomized clinical trials. Rev Psiquiatr Salud Ment 2011; 4: 126-143
    CrossrefPubMedGoogle Scholar
  • 17 Leucht S, Corves C, Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41
    CrossrefPubMedGoogle Scholar
  • 18 Lecrubier Y, Perry R, Milligan G. et al. Physician observations and perceptions of positive and negative symptoms of schizophrenia: a multinational, cross-sectional survey. Eur Psychiatry 2007; 22: 371-379
    CrossrefPubMedGoogle Scholar
  • 19 Haro JM, Edgell ET, Jones PB. et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003; 107: 222-232
    CrossrefPubMedGoogle Scholar
  • 20 Haro JM, Edgell ET, Novick D. et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111: 220-231
    CrossrefPubMedGoogle Scholar
  • 21 Dossenbach M, Arango-Davila C, Silva Ibarra H. et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005; 66: 1021-1030
    CrossrefPubMedGoogle Scholar
  • 22 Karagianis J, Novick D, Pecenak J. et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63: 1578-1588
    CrossrefPubMedGoogle Scholar
  • 23 APA. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Washington, DC: American Psychiatric Association (APA); 1994
    Google Scholar
  • 24 WHO. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organisation (WHO); 1992
    Google Scholar
  • 25 Haro JM, Kamath SA, Ochoa S. et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; DOI: 98. [pii]: 16–23
    PubMedGoogle Scholar
  • 26 Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Eribaum Associates; 1988
    Google Scholar
  • 27 Kirkpatrick B, Fenton WS, Carpenter Jr WT. et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006; 32: 214-219
    CrossrefPubMedGoogle Scholar
  • 28 Moller HJ, Muller H, Borison RL. et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45-49
    CrossrefPubMedGoogle Scholar
  • 29 Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol 2004; 19: 559-563
    CrossrefPubMedGoogle Scholar
  • 30 Turkoz I, Bossie CA, Dirks B. et al. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat 2008; 4: 949-958
    PubMedGoogle Scholar
  • 31 Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466-474
    CrossrefPubMedGoogle Scholar
  • 32 Haro JM, Novick D, Suarez D. et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26: 571-578
    CrossrefPubMedGoogle Scholar
  • 33 Haro JM, Suarez D, Novick D. et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007; 17: 235-244
    CrossrefPubMedGoogle Scholar
  • 34 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
    CrossrefPubMedGoogle Scholar
  • 35 Swartz MS, Perkins DO, Stroup TS. et al. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003; 29: 33-43
    CrossrefPubMedGoogle Scholar